Tolerx Inc.  has appointed Antonin de Fougerolles as chief scientific officer of the cancer, diabetes and autoimmune disease therapeutics firm. His role includeds overseeing the company’s research and development and growing Tolerx’s leadership in T cell immunology.
De Fougerolles previously worked at Alnylam Pharmaceuticals Inc. as vice president of research, immunology, metabolic and viral disease. In that role, helped develop the company’s research programs with partners Novartis and Roche. Prior to Alnylam, which he joined in 2003, he served as principal scientist at Biogen Idec Inc. De Fougerolles was responsible for research and development in Biogen’s immunology/inflammation-based programs.
De Fougerolles earned a doctorate degree in immunology from Harvard University and was a research fellow at Cambridge, England’s Laboratory of Molecular Biology.
Tolerx has developed as its lead drug candidate an antibody for newly diagnosed diabetics  that keeps the beta cell count high enough to produce some insulin. The drug, otelixizumab, is currently in Phase 3 development. The privately held Cambridge biotech also has three immune-building drug candidates in its pipeline to treat cancer and chronic infections.